Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 - Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ; Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ; Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ; Muro, Kei (Aichi Cancer Center Hospital) ; Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ; Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ; Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ; Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ; Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ; Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ; Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Be the first to review this document.

Add review

Rate this article:
Give a title to your review:
Write your review:
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.